Based on outcomes of the BIOSOLVE-II study, a novel second generation drug-eluting absorbable metal scaffold gained CE-mark in 2016. The BIOSOLVE-III study aimed to confirm these outcomes and to obtain additional 12-month angiographic data.
Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III / Haude, Michael; Ince, Hüseyin; Kische, Stephan; Abizaid, Alexandre; Tölg, Ralph; Alves Lemos, Pedro; Van Mieghem, Nicolas M; Verheye, Stefan; von Birgelen, Clemens; Christiansen, Evald Høj; Barbato, Emanuele; Garcia-Garcia, Hector M; Waksman, Ron. - In: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. - ISSN 1522-726X. - (2018). [10.1002/ccd.27680]
Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III
Barbato, EmanueleMembro del Collaboration Group
;
2018
Abstract
Based on outcomes of the BIOSOLVE-II study, a novel second generation drug-eluting absorbable metal scaffold gained CE-mark in 2016. The BIOSOLVE-III study aimed to confirm these outcomes and to obtain additional 12-month angiographic data.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
